Log in to save to my catalogue

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled...

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_527699

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

About this item

Full title

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

Publisher

Kidlington: Elsevier Ltd

Journal title

The Lancet (British edition), 2013-10, Vol.382 (9902), p.1424-1432

Language

English

Formats

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. Methods In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, child...

Alternative Titles

Full title

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_527699

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_527699

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(13)61091-0